NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis → Government’s chilling plan to control your money (From Weiss Ratings) (Ad) Free CARM Stock Alerts $1.52 +0.24 (+18.75%) (As of 06/28/2024 ET) Add Compare Share Share Today's Range$1.42▼$1.9050-Day Range$1.01▼$1.8752-Week Range$0.99▼$9.77Volume25.18 million shsAverage Volume465,224 shsMarket Capitalization$63.14 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Carisma Therapeutics alerts: Email Address Carisma Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside492.1% Upside$9.00 Price TargetShort InterestBearish6.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.56) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector671st out of 919 stocksPharmaceutical Preparations Industry311th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.79% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 3.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 1.9 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Carisma Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDid Joe Biden just reveal his replacement?The Democrats are scheming to remove Biden as their presidential nominee… And absolute chaos will ensue.I’ve created a crisis plan with everything you need to know right here. About Carisma Therapeutics Stock (NASDAQ:CARM)Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Read More CARM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARM Stock News HeadlinesJune 28 at 2:48 AM | americanbankingnews.comCarisma Therapeutics (NASDAQ:CARM) Rating Reiterated by HC WainwrightJune 27 at 4:30 PM | prnewswire.comCarisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaJune 29, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 25, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Stifel 2024 Cell Therapy ForumJune 25, 2024 | prnewswire.comCarisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid TumorsJune 13, 2024 | prnewswire.comCarisma Therapeutics Announces Adjournment of Annual Meeting of StockholdersMay 30, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 20, 2024 | msn.comCarisma Therapeutics Launches First Human Trial for CAR-Monocyte TherapyJune 29, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer TherapyMay 17, 2024 | markets.businessinsider.comThe Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 ExpertsMay 16, 2024 | prnewswire.comCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteMay 14, 2024 | finance.yahoo.comIs There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?May 13, 2024 | msn.comCarisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis TreatmentMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment DevelopmentsMay 10, 2024 | markets.businessinsider.comBuy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market GrowthMay 9, 2024 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | prnewswire.comCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | prnewswire.comCarisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024May 7, 2024 | msn.comCarisma Therapeutics Appoints Renowned Oncologist as Chief Medical OfficerMay 6, 2024 | prnewswire.comCarisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 2, 2024 | prnewswire.comCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerApril 24, 2024 | finance.yahoo.comCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingApril 22, 2024 | prnewswire.comCarisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ OutlookApril 12, 2024 | markets.businessinsider.comPromising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating AnalysisApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline PotentialSee More Headlines Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/29/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+492.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,880,000.00 Net Margins-538.81% Pretax Margin-539.53% Return on Equity-215.95% Return on Assets-80.58% Debt Debt-to-Equity Ratio0.08 Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$15.07 million Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book2.30Miscellaneous Outstanding Shares41,543,000Free Float34,481,000Market Cap$63.15 million OptionableNo Data Beta1.35 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Steven Kelly (Age 59)President, CEO & Director Comp: $786.91kMr. Michael Klichinsky Ph.D. (Age 34)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Comp: $525.43kMr. Richard S. Morris CPA (Age 50)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Comp: $584.85kDr. Saar Gill M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardMr. Eric H. Siegel J.D. (Age 59)MBA, General Counsel & Corporate Secretary Ms. Terry ShieldsSenior Vice President of Human ResourcesMr. Tom Wilton (Age 50)Chief Business Officer Dr. Eugene P. Kennedy F.A.C.S. (Age 55)M.D., Chief Medical Officer Mr. Kenneth LockeSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNCytosorbentsNASDAQ:CTSOExagenNASDAQ:XGNAspira Women's HealthNASDAQ:AWHAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 11,200 shares on 5/10/2024Ownership: 3.803%Empowered Funds LLCSold 21,150 shares on 5/7/2024Ownership: 0.065%View All Institutional Transactions CARM Stock Analysis - Frequently Asked Questions Should I buy or sell Carisma Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares. View CARM analyst ratings or view top-rated stocks. What is Carisma Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for Carisma Therapeutics' shares. Their CARM share price targets range from $6.00 to $12.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 492.1% from the stock's current price. View analysts price targets for CARM or view top-rated stocks among Wall Street analysts. How have CARM shares performed in 2024? Carisma Therapeutics' stock was trading at $2.93 at the beginning of 2024. Since then, CARM stock has decreased by 48.1% and is now trading at $1.52. View the best growth stocks for 2024 here. When is Carisma Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CARM earnings forecast. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.09. The business earned $3.40 million during the quarter, compared to the consensus estimate of $3.90 million. Carisma Therapeutics had a negative trailing twelve-month return on equity of 215.95% and a negative net margin of 538.81%. Who are Carisma Therapeutics' major shareholders? Carisma Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Empowered Funds LLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARM) was last updated on 6/29/2024 by MarketBeat.com Staff From Our PartnersJoe Biden Facing Political “Knockout” In Weeks?Joe Biden Facing Political “Knockout” In Weeks? Weeks from now, we are expecting Joe Biden to make a histor...Banyan Hill Publishing | SponsoredBiden’s inner circle turns against him?On August 19, the Democratic party will take the stage in Chicago and officially nominate their presidential c...Paradigm Press | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.